Randomized Double-Blind Trial of Sulindac and Etodolac to Eradicate Aberrant Crypt Foci and to Prevent Sporadic Colorectal Polyps
Open Access
- 1 June 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (11), 3803-3811
- https://doi.org/10.1158/1078-0432.ccr-10-2395
Abstract
Purpose: On the basis of the results of our preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention of colorectal cancer. Experimental design: Randomly assigned to sulindac (300 mg daily), etodolac (400 mg daily), and placebo groups were 189 subjects without polyps or who had undergone polypectomy. Drugs were administered for 2 months. ACF in the rectal region were counted by magnifying endoscopy. Occurrence of polyps was evaluated at 12 months. A planned interim analysis was conducted. Results: ACF number at 2 months was significantly suppressed in the sulindac group (P = 0.0075), but not in the etodolac group (P = 0.73). In the sulindac group, the numbers of adenomas plus hyperplastic polyps (total polyps) and adenomas at 12 months were significantly (P = 0.02) and marginally (P = 0.064) lower, respectively, in comparison with the placebo group; no such difference was observed in the etodolac group. In analysis of only polypectomized subjects, the numbers of total polyps and adenomas in the sulindac group were even more markedly lower, with P values of 0.014 and 0.034, respectively. A similar tendency was confirmed by analyses of the incidence of polyps at 12 months. Suppression rates of total polyps and adenomas in ACF responders to sulindac were significantly greater than in nonresponders. In all groups, compliance was more than 90% and no intolerable adverse effects were observed. Conclusions: ACF may be useful as surrogate lesions for chemoprevention of colorectal cancer. Clin Cancer Res; 17(11); 3803–11. ©2011 AACR.Keywords
Other Versions
This publication has 34 references indexed in Scilit:
- A Multicenter Study of Prevalence and Risk Factors for Aberrant Crypt FociClinical Gastroenterology and Hepatology, 2009
- Celecoxib for the Prevention of Colorectal Adenomatous PolypsThe New England Journal of Medicine, 2006
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasThe New England Journal of Medicine, 2006
- Suppression of azoxymethane‐induced colon cancer development in rats by a cyclooxygenase‐1 selective inhibitor, mofezolacCancer Science, 2006
- COX-2: A Molecular Target for Colorectal Cancer PreventionJournal of Clinical Oncology, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionThe New England Journal of Medicine, 2005
- Diet and cancer — the European Prospective Investigation into Cancer and NutritionNature Reviews Cancer, 2004
- A Randomized Trial of Aspirin to Prevent Colorectal AdenomasThe New England Journal of Medicine, 2003
- A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal CancerThe New England Journal of Medicine, 2003